Reabold Resources, Versarien, Toople, Nuformix and Russ Mould
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Reabold Resources, Versarien, Toople, Nuformix and Russ Mould
Stephen Williams, Co-Chief Executive Officer of Reabold Resources (RBD) discusses the spudding of the Burnett 2B well within the Monroe Swell field, onshore California.
Reabold Resources plc is an investing company investing in the exploration and production ("E&P") sector. The Company's investing policy is to acquire direct and indirect interests in exploration and producing projects and assets in the natural resources sector, and consideration is currently given to investment opportunities anywhere in the world.
Neill Ricketts, Chief Executive Officer of Versarien (VRS) provide an update on their operations in the U.S.
Versarien plc (VRS), is an advanced engineering materials group. Leveraging proprietary technology, the Group creates innovative engineering solutions for its clients in a diverse range of industries. Versarien has five subsidiaries operating under two divisions: Graphene and Plastics Thermal and Hardware Products. (Interview starts at 7 minutes 58 seconds)
Andy Hollingworth, Chief Executive Officer of Toople (TOOP) give an operational update based on their AGM statement.
Toople Plc, a company incorporated in the UK provides a range of telecoms services primarily targeted at the UK SME market. Services offered by the Group include business broadband, fibre, EFM and Ethernet data services, business mobile phones, cloud PBX and SIP Trunking and Traditional Services (calls and lines) all of which are delivered and managed through Merlin, the Group’s proprietary software platform. (Interview starts at 14 minutes 18 seconds)
Dr Dan Gooding, CEO, Nuformix plc (NFX) talks about commencement of clinical studies for the Company's lead asset NXP001.
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules. Nuformix has created an IP portfolio of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002. (Interview starts at 21 minutes 8 seconds)
Russ Mould, Investment Director at stockbroker AJ Bell talks about:
Uber
Lyft
Zotefoams (ZTF)
Mercantile Ports & Logistics (MPL)
Royal Dutch Shell (RDSB)
(Interview starts at 30 minutes 22 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.